Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et vindue med muligheder for at lære, om Linvoseltamab er sikkert og veltolereret, og hvor godt det virker hos deltagere med nyligt diagnosticeret myelomatose, som ikke allerede har modtaget behandling. (LINKER-MM4)

5. november 2026 opdateret af: Regeneron Pharmaceuticals

Fase 1/2 undersøgelse af Linvoseltamab (Anti-BCMA X Anti-CD3 bispecifikt antistof) hos tidligere ubehandlede patienter med symptomatisk myelomatose

This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible).

The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage) of linvoseltamab in study participants with NDMM as a first step in determining if the study drug has a role in the treatment of NDMM.

This study consists of 2 phases:

  • In Phase 1 Parts A and B, the study drug will be given to participants to study the side effects of the study drug and to establish the regimen (initial doses and full dose) of the study drug to be given to participants in Phase 2.
  • In Phase 1 Part C, the study drug will be given to participants to study the side effects when using different initial doses of the study drug.
  • In Phase 2, the study drug will be given to more participants to continue to assess the side effects of the study drug and to evaluate the activity of the study drug to shrink the tumor (multiple myeloma) in participants with NDMM.

The study is looking at several research questions, including:

  • What side effects may happen from taking linvoseltamab?
  • What the right dosing regimen is for linvoseltamab?
  • How many participants treated with linvoseltamab have improvement of their disease and for how long?
  • The effects of linvoseltamab study treatment before and after transplant
  • How much linvoseltamab is in the blood at different times?
  • Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects).

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

148

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Los Angeles, California, Forenede Stater, 90095
        • University of California Los Angeles (UCLA)
      • Orange, California, Forenede Stater, 92868
        • UC Irvine Health
    • Colorado
      • Denver, Colorado, Forenede Stater, 80218
        • Colorado Blood Cancer Institute/SCRI
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40207
        • Norton Cancer Institute
    • Michigan
      • Detroit, Michigan, Forenede Stater, 48201
        • Karmanos Cancer Institute
    • New Jersey
      • New Brunswick, New Jersey, Forenede Stater, 08901
        • Rutgers Cancer Institute of New Jersey
    • New York
      • Mineola, New York, Forenede Stater, 11501
        • Perlmutter Cancer Center at NYU Langone Hospital - Long Island
      • New York, New York, Forenede Stater, 10016
        • Perlmutter Cancer Center
      • New York, New York, Forenede Stater, 10032
        • Columbia University _ New York Presbyterian
      • Stony Brook, New York, Forenede Stater, 11794
        • Stony Brook University Hospital
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28204
        • Levine Cancer Institute
      • Durham, North Carolina, Forenede Stater, 27705
        • Duke University Health System (DUHS)
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • The University of Texas MD Anderson Cancer Center
      • Lille, Frankrig, 59000
        • CHU De Lille
      • Montpellier, Frankrig, 342950
        • Centre Hospitalier Universitaire (CHU) Montpellier
      • Paris, Frankrig, 75010
        • Hopital Saint Louis
      • Paris, Frankrig, 75651
        • University Hospitals Pitie Salpetriere - Charles Foix
    • Vienne
      • Poitiers, Vienne, Frankrig, 86021
        • Centre Hospitalier Universitaire (CHU) de Poitiers
    • Île-de-France Region
      • Antony, Île-de-France Region, Frankrig, 92160
        • Hopital Prive d'Antony
      • Paris, Île-de-France Region, Frankrig, 75015
        • Hopital Necker
      • Villejuif, Île-de-France Region, Frankrig, 94800
        • Gustave Roussy
      • Barcelona, Spanien, 08036
        • Hospital Clinic de Barcelona
      • Barcelona, Spanien, 08908
        • Institut Catala dOncologia (ICO Hospitalet)
      • Madrid, Spanien, 28027
        • Clinica Universidad de Navarra - Madrid
      • Madrid, Spanien, 28006
        • Universitary Hospital La Princesa
      • Salamanca, Spanien, 37007
        • Hospital Universitario de Salamanca
      • Valencia, Spanien, 46026
        • Hospital Universitari i Politecnic La Fe
    • Barcelona
      • Badalona, Barcelona, Spanien, 08916
        • Hospital Germans Trias i Pujol
    • Madrid
      • Pozuelo de Alarcón, Madrid, Spanien, 28223
        • Hospital Universitario Quiron Salud Madrid
    • Navarre
      • Pamplona, Navarre, Spanien, 31008
        • Clinica Universidad de Navarra
    • Principality of Asturias
      • Oviedo, Principality of Asturias, Spanien, 33011
        • Hospital Universitario Central de Asturias
    • Valencia
      • Alicante, Valencia, Spanien, 03010
        • Hospital General Universitario Doctor Balmis Alicante

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  2. Confirmed diagnosis of symptomatic Multiple Myeloma (MM) by International Myeloma Working Group (IMWG) diagnosis criteria, as described in the protocol
  3. Response-evaluable myeloma, according to the 2016 IMWG response criteria, as defined in the protocol
  4. No prior therapy for MM, with the exception of prior emergent or palliative radiation and up to 1 month of single-agent corticosteroids, with washout periods as per the protocol
  5. Participants must have evidence of adequate bone marrow reserves and hepatic, renal and cardiac function as defined in the protocol
  6. Participants must be age <70 and have adequate hepatic, renal, pulmonary and cardiac function to be considered transplant-eligible. The specific thresholds for adequate organ function are as per institutional guidance.

Key Exclusion Criteria:

  1. Receiving any concurrent investigational agent with known or suspected activity against MM, or agents targeting the A proliferation-inducing ligand (APRIL)/ Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI)/BCMA axis
  2. Known Central Nervous System (CNS) involvement with MM, known or suspected Progressive Multifocal Leukoencephalopathy (PML), a history of neurocognitive conditions, or CNS movement disorder, or history of seizure within 12 months prior to study enrollment
  3. Rapidly progressive symptomatic disease, (e.g. progressing renal failure or hypercalcemia not responsive to standard medical interventions), in urgent need of treatment with chemotherapy
  4. Diagnosis of non-secretory MM, active plasma cell leukemia primary light-chain (AL) amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or known POEMS syndrome (Plasma cell dyscrasia with polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes)

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Phase 1 cohorts

Linvoseltamab dose escalation (part A), dose expansion (part B), and evaluation of alternative step-up regimen (part C) for participants with NDMM who are treatment-naïve.

Linvoseltamab will be administered by intravenous (IV) infusion

Andre navne:
  • REGN5458
  • Lynozyfic ™
Eksperimentel: Phase 2 - transplant ineligible cohort

Transplant-ineligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen until disease progression as per protocol.

Linvoseltamab will be administered by intravenous (IV) infusion

Andre navne:
  • REGN5458
  • Lynozyfic ™
Eksperimentel: Phase 2 - transplant eligible cohort

Transplant-eligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen for a fixed duration of treatment as per protocol

Linvoseltamab will be administered by intravenous (IV) infusion

Andre navne:
  • REGN5458
  • Lynozyfic ™

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of Dose-Limiting Toxicities (DLTs)
Tidsramme: End of the Observation period; up to day 28

Phase 1

End of the Observation period; up to day 28
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 1

Post-Last Linvoseltamab Dose, up to 90 days
Severity of TEAEs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 1

Post-Last Linvoseltamab Dose, up to 90 days
Incidence of Adverse Events of Special Interest (AESIs)
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 1

Post-Last Linvoseltamab Dose, up to 90 days
Severity of AESIs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 1

Post-Last Linvoseltamab Dose, up to 90 days
Proportion of participants with a Very Good Partial Response (VGPR) or better using the International Myeloma Working Group (IMWG) response criteria
Tidsramme: Up to 5 years

Phase 2

Up to 5 years
Proportion of participants achieving Minimal Residual Disease (MRD) negative status (at 10^-5) after induction with consolidation therapy
Tidsramme: Up to 5 years

Phase 2 Transplant-eligible cohort

Up to 5 years
Proportion of participants achieving MRD-negative status (at 10^-5) after induction without consolidation therapy
Tidsramme: Up to 5 years

Phase 2 Transplant-eligible cohort

Up to 5 years
Proportion of participants achieving MRD-negative status as their best response after treatment period I with continuing to treatment period II
Tidsramme: Up to 5 years

Phase 2 Transplant-ineligible cohort

Up to 5 years
Proportion of participants achieving MRD-negative status as their best response after treatment period I without continuing to treatment period II
Tidsramme: Up to 5 years

Phase 2 Transplant ineligible cohort

Up to 5 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Concentrations of Linvoseltamab in serum
Tidsramme: Post-Last Linvoseltamab Dose, up to 12 weeks

Phases 1 and 2

Post-Last Linvoseltamab Dose, up to 12 weeks
Concentrations of total soluble B-Cell Maturation Antigen (BCMA)
Tidsramme: Post-Last Linvoseltamab Dose, up to 12 weeks

Phases 1 and 2

Post-Last Linvoseltamab Dose, up to 12 weeks
Incidence of Anti-Drug Antibodies (ADAs) to Linvoseltamab
Tidsramme: Post-Last Linvoseltamab Dose, up to 30 days

Phases 1 and 2

Post-Last Linvoseltamab Dose, up to 30 days
Magnitude of ADAs to Linvoseltamab
Tidsramme: Post-Last Linvoseltamab Dose, up to 30 days

Phases 1 and 2

Post-Last Linvoseltamab Dose, up to 30 days
Objective Response Rate (ORR) measured using the IMWG criteria
Tidsramme: Up to 5 years

Phase 1

Up to 5 years
Duration Of Response (DOR) measured using the IMWG criteria
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 1

Post-Last Linvoseltamab Dose, up to 90 days
Progression-Free Survival (PFS) measured using the IMWG criteria
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 1

Post-Last Linvoseltamab Dose, up to 90 days
Proportion of participants achieving MRD-negative status (at 10^-5) in participants with NDMM measured using the IMWG criteria
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 1

Post-Last Linvoseltamab Dose, up to 90 days
Incidence of TEAEs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
Severity of TEAEs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
Incidence of AESIs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
Severity of AESIs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
ORR of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tidsramme: Up to 5 years

Phase 2

Up to 5 years
MRD-negative status of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
DOR of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
PFS of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
Overall Survival (OS) of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
Time To Response (TTR) as measured using the IMWG criteria
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
ORR by risk levels
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
MRD-negative status by risk levels
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
DOR by risk levels
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
TTR by risk levels
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
PFS by risk levels
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
Incidence of MRD-negative status
Tidsramme: Up to 5 years

Phase 2

Up to 5 years
Cluster of Differentiation 34+ (CD34+) stem cell yield
Tidsramme: At cycle 4 of induction (each cycle is 28 days long)

Phase 2 Transplant-eligible cohort

At cycle 4 of induction (each cycle is 28 days long)
Time to neutrophil engraftment
Tidsramme: Up to 100 days post-transplant

Phase 2 Transplant-eligible cohort

Up to 100 days post-transplant
Time to platelet engraftment
Tidsramme: Up to 100 days post-transplant

Phase 2 Transplant-eligible cohort

Up to 100 days post-transplant
PFS after ASCT followed by 3 cycles of linvoseltamab
Tidsramme: Up to 5 years

Phase 2 Transplant-eligible cohort

Up to 5 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. december 2023

Primær færdiggørelse (Anslået)

2. november 2035

Studieafslutning (Anslået)

2. november 2035

Datoer for studieregistrering

Først indsendt

12. april 2023

Først indsendt, der opfyldte QC-kriterier

12. april 2023

Først opslået (Faktiske)

25. april 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • R5458-ONC-2158
  • 2022-500800-24-00 (Ctis)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

IPD-delingstidsramme

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD-delingsadgangskriterier

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .